Sunday, September 22, 2024 10:36:43 AM
Its all a carrot dangling exercise to find the next set of bagholders!
If they strike a non dilutive partnership where a big pharma gets exclusive right to combine L with their therapy for a particular indication then there is no reason to wait for UK approval.
NWBO was trading at over 3-4 X the market cap in December. They could have announced a partnership deal when the UK application was filed and they wouldn't have to dilute all the shares they did in the last 9 months. Importantly, it would have given them the cash to accelerate combo clinical trial too and the share price wouldn't be languishing if big pharma backed them.
I seriously doubt we will get back to the same market cap as we were back in Dec 2023 with the announcement of UK approval. So in the end there is no benefit of waiting even if market cap and share price was ever a consideration. The management continue to expose themselves by not executing on reimbursement and other regulatory submission since then (plus ongoing heavy dilution). There is decreasing amount of trust in the management crew to deliver return on investment as time goes by.
If they strike a non dilutive partnership where a big pharma gets exclusive right to combine L with their therapy for a particular indication then there is no reason to wait for UK approval.
NWBO was trading at over 3-4 X the market cap in December. They could have announced a partnership deal when the UK application was filed and they wouldn't have to dilute all the shares they did in the last 9 months. Importantly, it would have given them the cash to accelerate combo clinical trial too and the share price wouldn't be languishing if big pharma backed them.
I seriously doubt we will get back to the same market cap as we were back in Dec 2023 with the announcement of UK approval. So in the end there is no benefit of waiting even if market cap and share price was ever a consideration. The management continue to expose themselves by not executing on reimbursement and other regulatory submission since then (plus ongoing heavy dilution). There is decreasing amount of trust in the management crew to deliver return on investment as time goes by.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
